纤溶酶原激活物抑制剂-1（PAI-1）4G/5G 多态性与阿尔茨海默病、代谢综合征和女性不孕风险的关联：一项荟萃分析。
Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis.
机构信息
Department of Neurology, Shenyang First People's Hospital, Dadong District.
Department of Nerve Function, ShengJing Hospital of China Medical University, Heping District, Shenyang, Liaoning Province, People's Republic of China.
出版信息
Medicine (Baltimore). 2020 Dec 11;99(50):e23660. doi: 10.1097/MD.0000000000023660.
BACKGROUND
Plasminogen activator inhibitor-1 (PAI-1) is considered to be involved in the physiopathological mechanisms of Alzheimer's disease (AD), metabolic syndrome (MetS), and female infertility. Previous studies investigating the association between PAI-14G/5G (rs1799889) gene polymorphism and the risk of AD, MetS, and female infertility have reported inconsistent results. The aim of the present study was to investigate possible associations.
METHODS
Eligible studies were retrieved through PubMed, Medline, EMBASE, CNKI, and WANFANG databases. The odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the associations. Subgroup analyses by ethnicity and mean age, sensitivity analyses, and publication bias were performed.
RESULTS
Five studies (four articles) for AD, six studies (six articles) for MetS, and four studies (four articles) for female infertility were included in this meta-analysis. Our results showed no significant associations between the PAI-14G/5G polymorphism and the risk of AD and female infertility in five genetic models. For the risk of MetS, the PAI-1 4G/5G (rs1799889) polymorphism may be associated with the risk of MetS (4G vs 5G, OR = 1.31, 95%CI = 1.04-1.64, P = .021), especially in Asians (4G/4G vs 4G/5G+5G/5G, OR = 1.38, 95%CI = 1.01-1.87, P = .041) and patients with mean age > 50 years old (4G/4G vs 4G/5G+5G/5G, OR = 1.36, 95%CI = 1.03-1.78, P = .029).
CONCLUSION
The present meta-analysis suggested that the PAI-1 4G/5G polymorphism might be associated with the risk of MetS, but no evidence was detected for AD and female infertility.
背景
纤溶酶原激活物抑制剂-1（PAI-1）被认为与阿尔茨海默病（AD）、代谢综合征（MetS）和女性不孕的病理生理机制有关。先前研究 AD、MetS 和女性不孕与 PAI-14G/5G（rs1799889）基因多态性之间关联的研究结果并不一致。本研究旨在探讨可能的相关性。
方法
通过 PubMed、Medline、EMBASE、CNKI 和 WANFANG 数据库检索符合条件的研究。使用比值比（OR）和 95%置信区间（CI）评估相关性。按种族和平均年龄进行亚组分析、敏感性分析和发表偏倚。
结果
本荟萃分析纳入了五项 AD 研究（四篇文章）、六项 MetS 研究（六篇文章）和四项女性不孕研究（四篇文章）。结果显示，五种遗传模型中 PAI-14G/5G 多态性与 AD 和女性不孕的风险均无显著相关性。对于 MetS 的风险，PAI-14G/5G（rs1799889）多态性可能与 MetS 的风险相关（4G 与 5G，OR=1.31，95%CI=1.04-1.64，P=0.021），尤其是在亚洲人群中（4G/4G 与 4G/5G+5G/5G，OR=1.38，95%CI=1.01-1.87，P=0.041）和平均年龄>50 岁的患者中（4G/4G 与 4G/5G+5G/5G，OR=1.36，95%CI=1.03-1.78，P=0.029）。
结论
本荟萃分析提示 PAI-14G/5G 多态性可能与 MetS 的风险相关，但未发现与 AD 和女性不孕相关的证据。
Zotero 插件